Latest Commercialisation News

Metallium Limited has kicked off commissioning at its Texas Technology Campus, sealed a multi-year feedstock deal with Glencore, and bolstered its balance sheet with a A$75 million capital raise, setting the stage for commercialisation in 2026.

Spenda Limited reports a 65% year-on-year jump in payment volumes and a 34% quarterly rise in cash receipts, alongside significant cost savings and leadership changes.

Melbana Energy’s Q4 2025 report reveals a complex quarter with drilling setbacks in Cuba due to partner payment issues, alongside significant resource upgrades offshore Australia.

Simble Solutions reported steady cash flow and operational growth in Q4 FY25, alongside a strategic acquisition and capital raise to bolster its energy intelligence offerings.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

Yojee Limited reports a robust cash reserve and significant progress in its MOSAIC platform beta testing, alongside new customer contracts and strategic leadership hires, setting the stage for its 2026 commercial rollout.

Axel REE Limited reports a remarkable 145% increase in rare earth elements and 339% gallium resource growth at its Caladão Project, alongside a metallurgical breakthrough that could slash development costs through in-situ leaching.

American Rare Earths has successfully produced Mixed Rare Earths Oxide from its Halleck Creek ore, marking a key technical milestone. The company also updated its resource estimate and strengthened leadership as it advances towards becoming a major U.S. rare earths supplier.

Syrah Resources reported a strong Q4 2025 with a 34% rise in graphite production and a strategic edge from US tariffs on Chinese imports. The company advances its Vidalia anode material facility amid growing demand for natural graphite outside China.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.